atai Life Sciences CEO spotlights psychedelic therapy milestones and upcoming catalysts [Video]

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.  

CEO and co-founder Florian Brand joined Proactive to discuss the company’s recent milestones including encouraging clinical trial results, what to expect from its ongoing research programs and upcoming catalysts for both the company and the broader psychedelics sector.

Proactive: In 2023, there was a big focus on psychedelic-based therapies for depression. Take us through some of the milestones you achieved.

FB: 2023 was a year where we remained highly committed to developing very differentiated and novel innovative mental health therapies. The team made a tremendous amount of progress with our own program as well as some of the new programs we onboarded.

Earlier in January, we announced the strategic investment in Beckley Psytechwhich has two depression programs in development, BLP-003 and ELE-101. Both are psychedelic and seem to fit into that two-hour treatment window …